Imatinib (Gleevec) (formerly STI571) has demonstrated high levels of efficacy in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST) and has been used in more than 12,000 patients participating in clinical trials. Experience from clinical trials with imatinib has largely demonstrated the drug to be well tolerated in humans. Common side effects, usually manageable, include nausea, rash, superficial edema, myelosuppression, muscle cramps, and elevated liver transaminases. With longer follow-up and with further experience with the treatment of patients outside of clinical trials, we are able to report on rarer toxicities, the identification of certain predictors of common toxicities, and the clinical experience with male fertility and pregnancy outcomes. Semin Hematol 40(suppl 2):21-25.
I
MATINIB MESYLATE (Gleevec or Glivec, Novartis, Switzerland) (formerly STI571) is an inhibitor of the BCR-ABL tyrosine kinase, the putative cause of chronic myelogenous leukemia (CML). As a targeted therapy for CML, imatinib has demonstrated high levels of efficacy. 6, 10, 11 Particularly among patients with chronic-phase disease, 8 imatinib achieves higher rates of major and complete cytogenetic responses than other CML therapies. 4 In addition to inhibiting the tyrosine kinase of BCR-ABL, imatinib also inhibits the tyrosine kinases associated with c-ABL, ARG, the platelet-derived growth factor receptor (PDGF-r), and c-Kit. 1, 2, 7, 9 Initially, there were safety concerns with imatinib because the effect of these other tyrosine kinases on normal cell function was not known. However, in preclinical models, imatinib was well tolerated, with the liver abnormalities identified as a potential concern. Interestingly, imatinib was not found to be either mutagenic or clastogenic. Other notable preclinical features include: imatinib was teratogenic in rats, but not rabbits, and impaired spermatogenesis occurred in rats, dogs, and monkeys. Because of the teratogenicity data in rats, when the imatinib human trials began, it was recommended that effective contraception be used during imatinib therapy to prevent pregnancy.
Imatinib has been well tolerated in clinical trials. The more common side effects reported include nausea, rash, superficial edema, myelosuppression, muscle cramps, and elevations in hepatic transaminases. With longer follow-up and experience with the drug, we are able to report on rarer toxicities, identify certain predictors of common toxicities, and describe the clinical experience with male fertility and pregnancy outcomes.
Methods
Toxicity data and adverse events were collected in phase II and phase III trials of imatinib in CML, and dosing details, efficacy, and tolerability of imatinib in these settings have previously been reported. 5, 8, 10, 11 Clinical trial safety experience is based on 260 patients treated with imatinib for blast crisis in Study 102, 235 patients treated for accelerated phase CML in Study 109, 532 patients treated for chronic-phase CML after failure or intolerance of interferon (IFN) in Study 110, and 553 patients treated in the imatinib arm of Study 106, a randomized trial of front-line treatment for chronic-phase CML comparing imatinib to IFN plus cytarabine. In general, patients with chronic-phase CML were treated with imatinib 400 mg daily, and patients with blast crisis or accelerated-phase CML were treated with imatinib 600 mg daily. Toxicities were graded according to National Cancer Institute Common Toxicity Criteria, version 2.0. 3 We reviewed the clinical trial databases, augmenting the safety data with results from longer term treatment and from Novartis Clinical Safety and Epidemiology reports with a special focus on rare, severe toxicities (grade 3 or 4 rash), delayed toxicities (late liver dysfunction), and issues related to fertility and pregnancy outcomes.
Results

Overview of Imatinib Safety From Phase II Trials
The side effect profile of imatinib therapy in CML was largely outlined by the safety data from the phase II trials. Study 102 was a phase II study for patients with CML blast crisis. The first 37 patients were treated with a dose of 400 mg/d, and the subsequent 223 were treated with a dose of 600 mg/d. In addition, within-patient dose escalation was permitted (from 400 to 600 mg, or from 600 to 800 mg, respectively) for patients who failed to respond or progressed at their starting dose. Study 109 was a phase II trial for patients with accelerated-phase CML in which the first 77 patients were treated at 400 mg/d and the subsequent 158 were treated with 600 mg, again with the allowance for within-patient dose escalation. Patients with chronic-phase CML who were refractory or intolerant to IFN therapy were treated in Study 110, with all 532 patients starting at a dose of 400 mg/d. Dose escalation to 600 mg and if needed, up to 800 mg was permitted in patients who failed to respond. Nonhematologic adverse events occurring in greater than 10% of patients with advanced disease treated in these three studies are shown in Table 1 . While grade 3 and 4 nonhematologic events were relatively uncommon, side effects of any grade that occurred relatively frequently, and were considered potentially clinically important included nausea, vomiting, diarrhea, superficial edema (including both periorbital and peripheral edema), muscle cramps, maculopapular rash, fatigue,and headache.
While uncommon, two events were felt to be potentially clinically important: severe fluid retention and hemorrhage. Less than 5% of patients experienced excessive, central fluid retention, which manifested itself as congestive heart failure, pleural effusion, ascites, pericardial effusion, and pulmonary edema. Grade 3 or 4 hemorrhage occurred in 2% to 19% of patients, with the higher incidence occurring among patients treated for blast crisis. Gastrointestinal (GI) hemorrhage occurred in 3% to 5% of patients but was considered drug-related in 0% to 2%, and severe in less than 1.5%. Thrombocytopenia, concomitant use of nonsteroidal anti-inflammatory drugs, and history of gastric ulcer were contributing factors to the development of GI hemorrhage. Cerebral hemorrhages were also observed, but were more likely to occur in patients with advanced CML in the setting of rapid disease progression with thrombocytopenia.
The potential clinical importance of edema and hemorrhage led to an analysis of potential predictors of these two adverse events. While higher drug exposure (measured by patients' imatinib steady-state plasma concentration) was associated with increased risk of developing edema in univariate analysis, in multivariate analysis, this association was not independent of older patient age and female gender as risks for edema. Similarly for hemorrhage, higher drug exposure was associated with increased hemorrhage risk in univariate analysis, but in multivariate analysis was not independent of older age, platelet count, concomitant medications (antacids, antifungals, antivirals, paracetamol), and advanced disease stage. It is notable that the concomitant medication use is also confounded by disease stage and with conditions that may predispose to hemorrhage such as peptic ulcer.
Hematologic and biochemical toxicities observed in the phase II studies are summarized in Table 2 . Greater levels of myelosuppression were seen in blast crisis and accelerated-phase patients than among patients with late chronic-phase CML.
Imatinib Safety Profile in Early-Stage CML
Study 106 was a randomized trial of imatinib versus IFN plus low-dose cytarabine for patients with newly diagnosed CML without prior treatment except hydroxyurea. Efficacy data from this study show that patients assigned to the imatinib arm were approximately five times more likely to achieve complete cytogenetic response and had longer time to progression than patients assigned to IFN plus cytarabine. 4 In terms of safety, two types of comparisons are useful for putting the use of imatinib as front-line therapy of CML in perspective. Compared with previously treated CML patients from Study 110, patients on Study 106 experienced less nausea of any grade (42.5% v 60%) and less vomiting of any grade (14.7% v 32%), a difference that may be partly attributed to the more common intake of food with the imatinib therapy and/or to the fact that patients on Study 106 were earlier in their disease course. Myelosuppression was also less profound in Study 106 than in Study 110 (Table 3) . Notably, grade 4 neutropenia was seen in only 2% of imatinib-treated patients on Study 106 versus 8% of patients on Study 110. Grade 4 thrombocytopenia occurred in less than 1% of patients on both studies.
Focus on Toxicities of Special Interest in Study 106
The incidence of selected toxicities is detailed in Table 4 . Because of the known risk of fluid retention, there was concern regarding the development of glaucoma, seizure, pulmonary edema, and pleural effusion with imatinib treatment. Such potentially serious events were not observed more frequently among patients in the imatinib arm of Study 106, compared with patients on the IFN arm. Similarly, the known risk of mild rash with imatinib led to concern about more severe skin adverse events. Exfoliative rash was observed in 0.5% of patients in Study 106, and the incidence of exfoliative rash across all studies was approximately 1:500. Preclinical data and the observance of elevated liver transaminases on phase II trials meant that liver toxicity was carefully monitored on Study 106. Grade 2 elevations in AST/ALT were observed in 6.7% of imatinib patients versus 17.6% of patients in the IFN plus cytarabine group, and the incidence of new grade 3 or 4 events was 4.2% versus 7.1%, respectively. In general, AST/ALT elevations occurred relatively early and resolved over 14 to 21 days with drug withdrawal, allowing imatinib to be restarted in most cases. In contrast, with longer follow-up, there have been reports of seven patients with late-onset liver toxicity, occurring 293 to 541 days after initiation of imatinib therapy. These late events were manifested by elevations of AST/ALT in all seven patients and elevations of bilirubin in four of seven. With withdrawal of imatinib therapy, these resolved to grade 1 or less in a median of 73 days (range, 42 to 126). Of the four patients who were subsequently rechallenged with imatinib, two had recurrences of the transaminase elevation while the other two did not.
Severe, exfoliative rashes (grade 3 to 4) have been reported in 19 patients with CML (approximately 1:500 patients of the 12,000 treated with imatinib from all studies). The events have generally occurred early in the treatment course. Two of the 19 patients were described as having Stevens-Johnson syndrome. One of these two patients with multiple medical problems and multiple concurrent medications died. The treating physician attributed the Stevens-Johnson syndrome to allopurinol. The second patient was treated with corticosteroids and rechallenged with imatinib successfully.
Male Fertility and Pregnancies Among Patients Treated With Imatinib
Preclinical safety data showed that imatinib was teratogenic in rats, but not rabbits. These observations led to the recommendation that women taking imatinib use appropriate methods of contraception. There was no evidence that imatinib was clastogenic or mutagenic, thus imatinib is not felt to be genotoxic, and spermatozoa are expected to be qualitatively normal. However, spermatogenesis was impaired in rats, dogs, and monkeys. This observation raised concern that men treated with imatinib may have reduced sperm counts. Clinical experience thus far has not shown this to be true. Although sperm counts were not required for assessment of toxicities in Study 106, inadequate sperm counts have not been reported. One patient was found to have a low-normal sperm count during an infertility work-up. With continued imatinib therapy, the count improved somewhat and conception occurred without medical intervention. A second patient had a normal sperm count while taking imatinib prior to banking sperm. In addition, among men being treated on clinical trials, there are reports of 13 pregnancies in the partners of men on imatinib, providing additional support that spermatogenesis is not impaired. Five additional pregnancies in partners of men taking imatinib have been reported from patients treated outside of clinical trials. The outcomes of these pregnancies are detailed in Table 5 .
Despite the recommendation not to conceive while undergoing imatinib therapy, there are reports of 26 pregnancies that have occurred (15 in clinical trials, 11 in nonclinical trials) among women taking imatinib. Pregnancy outcomes are detailed in Table 6 . Only one patient restarted imatinib while continuing to carry the pregnancy to term. In this patient, who was being treated for blast crisis CML, the imatinib was stopped at the time the pregnancy was diagnosed (approximately 22 weeks gestation), but restarted when the blast crisis relapsed. The patient continued imatinib with adequate control of blast crisis and ultimately delivered a normal infant. The pregnancy outcome data must be interpreted with extreme caution. Reports are anecdotal and thus the data may suffer from reporting bias. Although two normal infants have been born, this information is not sufficient to alter recommendations that women being treated with imatinib use effective forms of contraception throughout treatment. In the event of inadvertent conception on imatinib therapy, decisions will need to be highly individualized. Women must be apprised of the preclinical data showing teratogenicity, and they must be aware of the risk of disease progression during the time that imatinib must be stopped if the patient elects to continue the pregnancy. There are no data that show continued imatinib therapy during pregnancy can be recommended.
Conclusions
Continued follow-up of large cohorts of patients confirms that imatinib therapy is generally well tolerated. Side effects of nausea, vomiting, and myelosuppression are less common and less severe among patients treated in earlier stages of disease. Delayed liver toxicity occurs rarely, but may require permanent discontinuation of imatinib treatment. To date, there is no objective evidence of impaired spermatogenesis in men. Women treated with imatinib should be aware of the potential teratogenicity of imatinib, and should be counseled to use effective contraceptive methods throughout treatment. 
